<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00126191</url>
  </required_header>
  <id_info>
    <org_study_id>04-336</org_study_id>
    <nct_id>NCT00126191</nct_id>
  </id_info>
  <brief_title>Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma</brief_title>
  <official_title>Phase II Study of Intensive Chemotherapy and Rituximab in Burkitt Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn more about how well a chemotherapy regime including
      rituximab works in treating patients with Burkitt or atypical Burkitt lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Patients will be placed into one of two groups, &quot;low risk&quot; and &quot;high risk&quot;. &quot;Low risk&quot;
           disease is defined as one area of disease measuring less than 10cm and a normal blood
           test called LDH (lactate hydrogenase). Patients not fitting the &quot;low risk&quot; criteria are
           considered &quot;high risk&quot;.

        -  If the patient has &quot;low risk&quot; disease their treatment cycle consist of three cycles of
           A.

        -  If the patient has &quot;high risk&quot; disease they will receive Cycle A followed by cycle B
           which will then repeat.

        -  Cycle A consists of the drugs: rituximab, cyclophosphamide, oncovin, doxorubicin and
           methotrexate (R-CODOX-M). The treatment cycle is approximately 14 days. A spinal tap is
           performed on day 1 and day 3 of the cycle and the patient will be hospitalized until
           between day 11 and day 13. After the patient's blood counts return to normal(usually
           around day 21),the next round of treatment will occur.

        -  Cycle B consists of the drugs: rituximab, ifosfamide, VP-16 and ara-c (IVAC). The
           treatment cycle is approximately 5 days. A spinal tap is performed on day 4 and once
           blood counts return to normal the patient will start cycle A again.

        -  After the patient has finished the treatments, they will be re-evaluated with CT scans
           and PET scans to determine whether or not they are in remission. Every three months for
           two years, blood tests and CT and PET scans will be performed. Follow up after that will
           be every 6 months for two years.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    closed due to slow accrual
  </why_stopped>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rates (CR and PR) in Adults With Burkitt/Atypical Burkitt</measure>
    <time_frame>3 years</time_frame>
    <description>Complete Response (CR): Disappearance of all measurable or evaluable disease confirmed.
Partial Response (PR): Reduction of 50% or greater in the sum of the products of the perpendicular diameters of all measurable.
Of 8 High Risk participants, 7 met the primary response outcome. 1 High Risk participant did not meet protocol defined primary outcome response and died two months following enrollment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>Until disease progression up to 120 months</time_frame>
    <description>Participants are followed after completion of protocol therapy until disease progression to determine disease free survival.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Burkitt Lymphoma</condition>
  <condition>Non-Hodgkins Lymphoma</condition>
  <condition>Atypical Burkitt Lymphoma</condition>
  <arm_group>
    <arm_group_label>Low Risk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low-risk patients receive 3 cycles of regimen A.
Regimen A:
Rituximab (375 mg/m^2) on Days 1 and 3. Cyclophosphamide (800 mg/m^2) on days 1 and 2. Vincristine (1.4 mg/m^2) on days 1 and 10. Doxorubicin (50 mg/m^2) on Day 1. Methotrexate (3000 mg/m^2) on Day 10. Intrathecal Cytarabine (50mg) will be given on Day 1 and intrathecal methotrexate (12mg) will be given on Days 1 and 10.
Leucovorin on days 11 and 12.
Rituximab is given on Days 1 and 3 in cycle 1, and on Day 1 of all other cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Risk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High-risk patients receive 4 alternating cycles of regimens A and B (A-B-A-B).
Regimen A (as described earlier).
Regimen B:
Rituximab (375mg/m^2) on Day 1. Ifosfamide (1500mg/m^2) on Days 1-5. Mesna (275 mg/m^2) on Days 1-5. Etoposide (60mg/mg^2) on Days 1-5. Cytarabine (2 gm/m^2) twice a day on Days 1 and 2. Intrathecal methotrexate (12mg) on Day 5, and intrathecal methotrexate (50mg) on Day 3 (also on Day 1 for patients with central nervous system involvement).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Low Risk: Intravenously on Day 3 of the first cycle (One cycle is 14 days) then day 1 for next 2 cycles (Regimen A) High Risk: Regimen A followed by a 5-day cycle where rituximan is given on day 1</description>
    <arm_group_label>Low Risk</arm_group_label>
    <arm_group_label>High Risk</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Low Risk/High Risk: Intravenously on day 1 and day 2 of a 14-day cycle for 3 cycles (regimen A)</description>
    <arm_group_label>Low Risk</arm_group_label>
    <arm_group_label>High Risk</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Low Risk/High Risk: Given on day 1 of a 14-day cycle for 3 cycles (regimen A)</description>
    <arm_group_label>Low Risk</arm_group_label>
    <arm_group_label>High Risk</arm_group_label>
    <other_name>Adriamycin, Rubex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Low Risk/High Risk: Given intravenously on day 1 and day 10 of a 14-day cycle for 3 cycles (regimen A)</description>
    <arm_group_label>Low Risk</arm_group_label>
    <arm_group_label>High Risk</arm_group_label>
    <other_name>Oncovin, vincristine sulfate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Low Risk: Given on day 10 of a 14-day cycle for 3 cycles (regimen A) High Risk: Regimen A followed by methotrexate on day 3 and day 5 of a 5-day cycle</description>
    <arm_group_label>Low Risk</arm_group_label>
    <arm_group_label>High Risk</arm_group_label>
    <other_name>Rheumatrex, Trexall</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>Low Risk/High Risk: Given on days 11, 12 and 13 of a 14-day cycle for 3 cycles (regimen A)</description>
    <arm_group_label>Low Risk</arm_group_label>
    <arm_group_label>High Risk</arm_group_label>
    <other_name>Folinic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
    <description>High Risk: After Regimen A, Ifosomide given on days 1-5 of a 5 day cycle</description>
    <arm_group_label>High Risk</arm_group_label>
    <other_name>Ifex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>High Risk: After Regimen A, etoposide given days 1-5 of a 5-day cycle</description>
    <arm_group_label>High Risk</arm_group_label>
    <other_name>Vepesid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Low Risk: Given on days 1, 3, 5 and 10 of a 14-day cycle for 3 cycles (regimen A) High Risk: After regimen A, cytarabine given on days 1 and 2 of a 5-day cycle</description>
    <arm_group_label>Low Risk</arm_group_label>
    <arm_group_label>High Risk</arm_group_label>
    <other_name>Cytosar, Tarabine PFS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesna</intervention_name>
    <description>High Risk: After regimen A, mesna is given on days 1-5 of a 5-day cycle</description>
    <arm_group_label>High Risk</arm_group_label>
    <other_name>Mesnex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically documented Burkitt or atypical Burkitt according to World Health
             Organization (WHO) criteria.

          -  Pathology must be reviewed at the Brigham and Women's Hospital (BWH).

          -  Measurable or evaluable disease: Disease reproducibly measurable in two perpendicular
             dimensions on exam, computed tomography (CT), radiograph, or magnetic resonance
             imaging (MRI). Disease present on bone marrow biopsy will be considered as evaluable
             disease.

          -  The following may not be used as the sole site of measurable or evaluable disease:
             *ascites, *pleural effusion, *bone lesion or *central nervous system (CNS) disease.

          -  Age &gt; 18

          -  Laboratory data (within 2 weeks of study registration):

               -  ANC &gt; 1500/ul;

               -  platelet &gt; 100,000/ul;

               -  creatinine &lt; 1.5 X normal;

               -  creatinine clearance &gt; 60 ml/min;

               -  bilirubin &lt; 1.5 X normal;

               -  AST and ALT &lt; 2.5 X normal;

               -  alkaline phosphates &lt; 3 X normal;

               -  HIV negative;

               -  cardiac ejection fraction &gt; 50%.

        Exclusion Criteria:

          -  Previous chemotherapy or radiation therapy. Steroids of less than 72 hours duration
             for impending oncologic emergency are allowed.

          -  Uncontrolled bacterial, fungal, or viral infection.

          -  Concomitant malignancy excluding carcinoma in situ of the cervix and basal cell
             carcinoma of the skin.

          -  Serious comorbid disease. Clinically significant pulmonary symptomatology. In patients
             with a history of symptomatic pulmonary disease, pulmonary function tests (PFTs)
             should document an forced expiratory volume at 1 second (FeV1), forced vital capacity
             (FVC), and total lung capacity (TLC) of &gt; 60% predicted and carbon monoxide diffusing
             capacity of the lung (DLCO) of &gt; 50% predicted. No clinically significant cardiac
             symptomatology. The cardiac ejection fraction must be &gt; 50%.

          -  Pregnancy. All males and females with reproductive potential must consent to use an
             effective form of contraception while on study.

          -  Major surgery within the previous 2 weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ann S. La Casce, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2005</study_first_submitted>
  <study_first_submitted_qc>August 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2005</study_first_posted>
  <results_first_submitted>November 30, 2012</results_first_submitted>
  <results_first_submitted_qc>April 17, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 23, 2013</results_first_posted>
  <last_update_submitted>April 17, 2013</last_update_submitted>
  <last_update_submitted_qc>April 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Ann S. LaCasce, MD</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Burkitt Lymphoma</keyword>
  <keyword>atypical Burkitt lymphoma</keyword>
  <keyword>Non-Hodgkin's Lymphoma</keyword>
  <keyword>rituximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Burkitt Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Mesna</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This BL protocl was IRB approved 01/18/05, activated 7/18/05. Participants were identified either in the outpatient clinic at DFCI or while admitted to our partner inpatient hospital, Brigham &amp; Women's Hospital. The study was closed to accrual 6/2/08 due to slow accrual.</recruitment_details>
      <pre_assignment_details>Participants with previous chemotherapy or radiation, uncontrolled infection, concomitant malignancy (some exclusions), serious comorbid disease, pregnancy, and HIV+ were excluded. Subjects stratified according to risk: Single focus disease &lt;10cm and normal LGH=low risk, all others high risk.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Low Risk</title>
          <description>Regimen A. Single focus of disease less than 10 cm in greatest dimension and a normal LDH. Participants at low risk received three cycles of Regimen A (AAA).</description>
        </group>
        <group group_id="P2">
          <title>High Risk</title>
          <description>Regimen A followed by Regimen B. Cycles A and B will then be repeated (ABAB).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6">1 pt off study during cycle 1 due to toxicity</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Low Risk</title>
          <description>Regimen A. Single focus of disease less than 10 cm in greatest dimension and a normal LDH. Participants at low risk received three cycles of Regimen A (AAA).</description>
        </group>
        <group group_id="B2">
          <title>High Risk</title>
          <description>Regimen A followed by Regimen B. Cycles A and B will then be repeated (ABAB).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>IRB approved deviation to register 1 patient at age 17.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rates (CR and PR) in Adults With Burkitt/Atypical Burkitt</title>
        <description>Complete Response (CR): Disappearance of all measurable or evaluable disease confirmed.
Partial Response (PR): Reduction of 50% or greater in the sum of the products of the perpendicular diameters of all measurable.
Of 8 High Risk participants, 7 met the primary response outcome. 1 High Risk participant did not meet protocol defined primary outcome response and died two months following enrollment.</description>
        <time_frame>3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Risk</title>
            <description>Regimen A. Single focus of disease less than 10 cm in greatest dimension and a normal LDH. Participants at low risk received three cycles of Regimen A (AAA).</description>
          </group>
          <group group_id="O2">
            <title>High Risk</title>
            <description>Regimen A followed by Regimen B. Cycles A and B will then be repeated (ABAB).</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rates (CR and PR) in Adults With Burkitt/Atypical Burkitt</title>
          <description>Complete Response (CR): Disappearance of all measurable or evaluable disease confirmed.
Partial Response (PR): Reduction of 50% or greater in the sum of the products of the perpendicular diameters of all measurable.
Of 8 High Risk participants, 7 met the primary response outcome. 1 High Risk participant did not meet protocol defined primary outcome response and died two months following enrollment.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Free Survival</title>
        <description>Participants are followed after completion of protocol therapy until disease progression to determine disease free survival.</description>
        <time_frame>Until disease progression up to 120 months</time_frame>
        <population>One low-risk participant was lost to follow-up after 48 months of disease free survival.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Risk</title>
            <description>Regimen A. Single focus of disease less than 10 cm in greatest dimension and a normal LDH. Participants at low risk received three cycles of Regimen A (AAA).</description>
          </group>
          <group group_id="O2">
            <title>High Risk</title>
            <description>Regimen A followed by Regimen B. Cycles A and B will then be repeated (ABAB).</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Free Survival</title>
          <description>Participants are followed after completion of protocol therapy until disease progression to determine disease free survival.</description>
          <population>One low-risk participant was lost to follow-up after 48 months of disease free survival.</population>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" lower_limit="84" upper_limit="84"/>
                    <measurement group_id="O2" value="52" lower_limit="2" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Grade 4 hematologic toxicities were not considered to be serious adverse events in this Burkitts Lymphoma study. Hospitalization without accompanying SAE did not constitute SAE for this study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Low Risk</title>
          <description>Regimen A. Single focus of disease less than 10 cm in greatest dimension and a normal LDH. Participants at low risk received three cycles of Regimen A (AAA).</description>
        </group>
        <group group_id="E2">
          <title>High Risk</title>
          <description>Regimen A followed by Regimen B. Cycles A and B will then be repeated (ABAB).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE 3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title vocab="CRCAE 3.0">Bilirubin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to small numbers of subjects analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Ann LaCasce, MD</name_or_title>
      <organization>DFCI</organization>
      <phone>617-632-5959</phone>
      <email>ALACASCE@PARTNERS.ORG</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

